34696 Federal Register / Vol. 66, No. 126 / Friday, June 29, 2001 / Notices

respiratory and cardiac motion and

provide a synchronization signal. The

invention uses a mechanical linkage to

keep the pickup coil far from the center

of the scanner’s radio frequency and

gradient coils, thereby eliminating

artifacts in the sensor signal and

magnetic resonance images caused by

mutual inductance. The signal

generated by this device is proportional

to chest velocity rather than chest height

and is, therefore, free of any offset

voltages, permitting peak location with

a simple threshold detector, and is large

in amplitude even for small animal

subjects. The invention operates

without the need for any electrical leads

inside the magnet and thus eliminates

any burn hazards for the patient. This

device provides an inexpensive

alternative to commercially available

bellows sensors and fiber optically

coupled units. Unlike competing

sensors, this invention can be inserted,

removed, or adjusted without removing

the subject from the magnet and can

operate with the subject in a prone or

supine position. This invention has

applications in both animal and human

imaging studies.

Vessel Surface Reconstruction With a

Tubular Deformable Model

Yim et al. (CC)

[DHHS Reference No. E–239–01/0 filed 15

Feb 2001]

Licensing Contact: Dale Berkley; 301/

496–7735 ext. 223; e-mail:

berkleyd@od.nih.gov

The invention is a method for

modeling a carotid or renal artery to

measure stenosis from 3D angiographic

data that may otherwise exhibit limited

image resolution and contrast. The

method reconstructs vessel surfaces

from 3D angiographic data using a

deformable model that employs a

tubular coordinate system. Vertex

merging is incorporated into the

coordinate system to maintain even

vertex spacing and to avoid problems of

self-intersection of the surface. This

method produces reconstructed surfaces

that have a realistic smooth appearance

and accurately represent vessel shape.

The method allows for an objective

evaluation of vessel shape and may

improve the precision of shape

measurements from 3D angiography.

This abstract revises one published in

the Federal Register on Tuesday, May

20, 2001 (66 FR 29154) as DHHS

Reference No. E–202–00/1.

Development of Mutations Useful for

Attenuating Dengue Viruses and

Chimeric Dengue Viruses

Stephen S. Whitehead, Brian R.

Murphy, Kathryn A. Hanley, Joseph E.

Blaney Jr. (NIAID)

[DHHS Reference No. E–120–01/0 filed 22

May 2001]

Licensing Contact: Carol Salata; 301/

496–7735 ext. 232; e-mail:

salatac@od.nih.gov

Although flaviviruses cause a great

deal of human suffering and economic

loss, there is a shortage of effective

vaccines. This invention relates to

dengue virus mutations that may

contribute to the development of

improved dengue vaccines. Site directed

and random mutagenesis techniques

were used to introduce mutations into

the dengue virus genome and to

assemble a collection of useful

mutations for incorporation in

recombinant live attenuated dengue

virus vaccines. The resulting mutant

viruses were screened for several

valuable phenotypes, including

temperature sensitivity in Vero cells or

human liver cells, host cell restriction in

mosquito cells or human liver cells, host

cell adaptation for improved replication

in Vero cells, and attenuation in mice or

in mosquitoes. The genetic basis for

each observed phenotype was

determined by direct sequence analysis

of the genome of the mutant virus.

Mutations identified through these

sequencing efforts have been further

evaluated by re-introduction of the

identified mutations, singly, or in

combination, into recombinant dengue

virus and characterization of the

resulting recombinant virus for

phenotypes. In this manner, a menu of

attenuating and growth promoting

mutations was developed that is useful

in fine-tuning the attenuation and

growth characteristics of dengue virus

vaccine candidates. The mutations

promoting growth in Vero cells have

usefulness for the production of live or

inactivated dengue virus vaccines.

Subgenomic Replicons of the Flavivirus

Dengue

Xiaowu Pang (CBER/FDA)

[DHHS Reference No. E–228–00/0 filed 09

Mar 2001]

Licensing Contact: Carol Salata; 301/

496–7735 ext. 232; e-mail:

salatac@od.nih.gov

Dengue virus, with its four serotypes

Den-1 to Den-4, is the most important

member of the Flavivirus genus with

respect to infection of human producing

diseases that range from flu-like

symptoms of dengue fever (DF) to severe

or fatal illness of dengue hemorrhagic

fever (DHF) and dengue shock

syndrome (DSS). Dengue outbreaks

continue to be a major public health

problem in densely populated areas of

the tropical and subtropical regions,

where mosquito vectors are abundant.

This invention relates to the

construction of all four types of dengue

subgenomic replicons (chromosome and

plasmid which contain genetic

information necessary for their own

replication) containing large deletions

in the structural region (C-preM-E) of

the genome. Immunization using these

replicons should be effective in eliciting

not only a humoral-mediated immune

response but also a cell-mediated

immune response. These replicons

should be safer than a live attenuated

vaccine because they cannot cause

disease in the host and they should be

better than subunit vaccines because

they can replicate in the host.

Dated: June 22, 2001.

Jack Spiegel,

Director, Division of Technology Development

and Transfer, Office of Technology Transfer,

National Institutes of Health.

[FR Doc. 01–16366 Filed 6–28–01; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of

Closed Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of a meeting of the

Board of Scientific Counselors, National

Cancer Institute.

The meeting will be closed to the

public as indicated below in accordance

with the provisions set forth in section

552b(c)(6), Title 5 U.S.C., as amended

for the review, discussion, and

evaluation of individual intramural

programs and projects conducted by the

National Cancer Institute, including

consideration of personnel

qualifications and performance and the

competence of individual investigators,

the disclosure of which would

constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: Board of Scientific

Counselors, National Cancer Institute,

Subcommittee A-Clinical Sciences and

Epidemiology.

Date: July 23, 2001.

Time: 9 am to 3:30 p.m.

Agenda: To review and evaluate personal

qualifications and performance, and

competence of individual investigators.

Federal Register / Vol. 66, No. 126 / Friday, June 29, 2001 / Notices 34697

Place: National Cancer, Institute, Building

31, C Wing, 6th Floor, Conference Rooms 6,

9000 Rockville Pike, Bethesda, MD 20892.

Contact Person: Abby B. Sandler, Scientific

Review Administrator, Institute Review

Office, Office of the Director, National Cancer

Institute, National Institutes of Health, 6116

Executive Boulevard, room 7031, Rockville,

MD 20852, (301) 496–7628.

Any interested person may file written

comments with the committee by forwarding

the statement to the Contact Person listed on

this notice. The statement should include the

name, address, telephone number and when

applicable, the business or professional

affiliation of the interested person.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.392, Cancer Construction;

93.393, Cancer Cause and Prevention

Research; 93.394, Cancer Detection and

Diagnosis Research; 93.395, Cancer

Treatment Research; 93.396, Cancer Biology

Research; 93.397, Cancer Centers Support;

93.398, Cancer Research Manpower; 93.399,

Cancer Control, National Institutes of Health,

HHS)

Dated: June 20, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 01–16343 Filed 6–28–01; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of

Closed Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Cancer

Institute Special Emphasis Panel, P01

Program Project Application.

Date: July 19, 2001.

Time: 1 p.m. to 6 p.m.

Agenda: To review and evaluate grant

applications.

Place: National Cancer Institute, 6116

Executive Blvd., Room 8139, Rockville, MD

20852, (Telephone Conference Call).

Contact Person: Shakeel Ahmad, PhD,

Scientific Review Administrator, Grants

Review Branch, National Cancer Institute,

National Institutes of Health, 8th floor, room

8139, 6116 Executive Boulevard, Bethesda,

MD 20892, 301–594–0114.

Any interested person may file written

comments with the committee by forwarding

the statement to the Contact Person listed on

this notice. The statement should include the

name, address, telephone number and when

applicable, the business or professional

affiliation of the interested person.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.392, Cancer Construction;

93.393, Cancer Cause and Prevention

Research; 93.394, Cancer Detection and

Diagnosis Research; 93.395, Cancer

Treatment Research; 93.396, Cancer Biology

Research; 93.397, Cancer Centers Support;

93398, Cancer Research Manpower; 93.399,

Cancer Control, National Institutes of Health,

HHS)

Dated: June 20, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 01–16344 Filed 6–28–01; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of

Closed Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Cancer

Institute Special Emphasis Panel, Review of

a Program Project Grant Application.

Date: July 18–20, 2001.

Time: 7:30 p.m. to 12 p.m.

Agenda: To review and evaluate grant

applications.

Place: Sheraton Palo Alto, 625 El Camino

Real, Palo Alto, CA 94301.

Contact Person: William D. Merritt, PhD.,

Scientific Review Administrator, Grants

Review Branch, National Cancer Institute,

National Institutes of Health, 6116 Executive

Boulevard, Room 8034, MSC 8328, Bethesda,

MD 20892–8328, 301–496–9767.

Any interested person may file written

comments with the committee by forwarding

the statement to the Contact Person listed on

this notice. The statement should include the

name, address, telephone number and when

applicable, the business or professional

affiliation of the interested person.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.392, Cancer Construction;

93.393, Cancer Cause and Prevention

Research; 93.394, Cancer Detection and

Diagnosis Research; 93.395, Cancer

Treatment Research; 93.396, Cancer Biology

Research; 93.397, Cancer Centers Support;

93.398, Cancer Research Manpower; 93.399,

Cancer Control, National Institutes of Health,

HHS)

Dated: June 21, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 01–16348 Filed 6–28–01; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of

Closed Meetings

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meetings.

The meetings will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552(c)(6), Title 5 U.S.C.,

as amended. The contract proposals and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the contract

proposals, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Cancer

Institute Special Emphasis Panel,

Fundamental Technologies for the

Development of Biomolecular Sensors.

Date: July 24–25, 2001.

Time: 8 am to 6 pm.

Agenda: To review and evaluate contract

proposals.

Place: Ramada Inn, 1775 Rockville Pike,

Rockville, MD 20852.

Contact Person: Sherwood Githens,

Scientific Review Administrator, National

Institutes of Health, National Cancer

Institute, Special Review, Referral and

Resources Branch, 6116 Executive Boulevard,

Room 8068. Bethesda, MD 20892, (301) 435–

1822.

Name of Committee: National Cancer

Institute Special Emphasis Panel,

Fundamental Technologies for the

Development of Biomolecular Sensors.

Date: July 26–27, 2001.

Time: 8 am to 6 pm.